{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:40:38Z","timestamp":1759765238419,"version":"build-2065373602"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Turkish Society of Medical Oncology","award":["2022\/008"],"award-info":[{"award-number":["2022\/008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01323-8","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T02:47:24Z","timestamp":1759718844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum GFAP as a Potential Biomarker for Chemotherapy-Associated Cognitive Impairment in Elderly Patients with Gastrointestinal Cancers: An Exploratory Study"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-7284","authenticated-orcid":false,"given":"Ozgur","family":"Tanriverdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ummuhani","family":"Ozel-Turkcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.21.00239","volume":"39","author":"A Magnuson","year":"2021","unstructured":"Magnuson A, Ahles T, Chen BT, Mandelblatt J, Janelsins MC. Cognitive function in older adults with cancer: assessment, management, and research opportunities. J Clin Oncol. 2021;39:2138\u201349.","journal-title":"J Clin Oncol"},{"key":"1323_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jagp.2017.04.001","volume":"25","author":"JN Vega","year":"2017","unstructured":"Vega JN, Dumas J, Newhouse PA. Cognitive effects of chemotherapy and cancer-related treatments in older adults. Am J Geriatr Psychiatry. 2017;25:1415\u201326.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1323_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jgo.2016.04.008","volume":"7","author":"KP Loh","year":"2016","unstructured":"Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, et al. Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol. 2016;7:270\u201380.","journal-title":"J Geriatr Oncol"},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.3390\/cancers13246171","volume":"13","author":"M Dos Santos","year":"2021","unstructured":"Dos Santos M, Licaj I, Bellera C, Cany L, Binarelli G, et al. Cognitive impairment in older cancer patients treated with first-line chemotherapy. Cancers (Basel). 2021;13:6171.","journal-title":"Cancers (Basel)"},{"key":"1323_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1387251","volume":"14","author":"K Demos-Davies","year":"2024","unstructured":"Demos-Davies K, Lawrence J, Seelig D. Cancer related cognitive impairment: a downside of cancer treatment. Front Oncol. 2024;14: 1387251.","journal-title":"Front Oncol"},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"770413","DOI":"10.3389\/fmolb.2021.770413","volume":"8","author":"Z Orsz\u00e1ghov\u00e1","year":"2021","unstructured":"Orsz\u00e1ghov\u00e1 Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci. 2021;8:770413.","journal-title":"Front Mol Biosci"},{"key":"1323_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/cancers15030640","volume":"15","author":"YS Kao","year":"2023","unstructured":"Kao YS, Yeh CC, Chen YF. The relationship between cancer and dementia: an updated review. Cancers (Basel). 2023;15:640.","journal-title":"Cancers (Basel)"},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fnins.2015.00131","volume":"9","author":"EG Vichaya","year":"2015","unstructured":"Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, et al. Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015;9:131.","journal-title":"Front Neurosci"},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21037\/atm-20-6443","volume":"9","author":"L Bai","year":"2021","unstructured":"Bai L, Yu E. A narrative review of risk factors and interventions for cancer-related cognitive impairment. Ann Transl Med. 2021;9:72.","journal-title":"Ann Transl Med"},{"key":"1323_CR10","first-page":"694","volume":"20","author":"S Atasavun Uysal","year":"2022","unstructured":"Atasavun Uysal S, Yildiz Kabak V, Karakas Y, Karabulut E, Erdan Kocamaz D, et al. Investigation of the validity and reliability of the Turkish version of the Functional Assessment of Cancer Therapy-Cognitive Function in cancer patients. Palliat Support Care. 2022;20:694\u2013700.","journal-title":"Palliat Support Care"},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/SPC.0000000000000257","volume":"11","author":"E Isenberg-Grzeda","year":"2017","unstructured":"Isenberg-Grzeda E, Huband H, Lam H. A review of cognitive screening tools in cancer. Curr Opin Support Palliat Care. 2017;11:24\u201331.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13670-016-0182-9","volume":"5","author":"A Magnuson","year":"2016","unstructured":"Magnuson A, Mohile S, Janelsins M. Cognition and cognitive impairment in older adults with cancer. Curr Geriatr Rep. 2016;5:213\u20139.","journal-title":"Curr Geriatr Rep"},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38:364\u201374.","journal-title":"Trends Neurosci"},{"key":"1323_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom11091361","volume":"11","author":"AM Jurga","year":"2021","unstructured":"Jurga AM, Paleczna M, Kadluczka J, Kuter KZ. Beyond the GFAP-astrocyte protein markers in the brain. Biomolecules. 2021;11: 1361.","journal-title":"Biomolecules"},{"key":"1323_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis. Cells. 2023;12: 1309.","journal-title":"Cells"},{"key":"1323_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.37349\/ent.2023.00054","volume":"3","author":"JJ Miguel-Hidalgo","year":"2023","unstructured":"Miguel-Hidalgo JJ. Neuroprotective astroglial response to neural damage and its relevance to affective disorders. Explor Neuroprotective Ther. 2023;3:328\u201345.","journal-title":"Explor Neuroprotective Ther"},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13:68.","journal-title":"Alzheimers Res Ther"},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, Tabernero J, Hickish T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109\u201316.","journal-title":"J Clin Oncol"},{"key":"1323_CR19","unstructured":"National Comprehensive Cancer Network (NCCN) Guidelines. Treatment by cancer types. 2025. https:\/\/www.nccn.org\/guidelines\/category_1. (Last available date: 26.01.2025)."},{"key":"1323_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00004356-200503000-00011","volume":"28","author":"AA K\u00fc\u00e7\u00fckdeveci","year":"2005","unstructured":"K\u00fc\u00e7\u00fckdeveci AA, Kutlay S, Elhan AH, Tennant A. Preliminary study to evaluate the validity of the mini-mental state examination in a normal population in Turkey. Int J Rehabil Res. 2005;28:77\u20139.","journal-title":"Int J Rehabil Res"},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"fcae396","DOI":"10.1093\/braincomms\/fcae396","volume":"6","author":"F Leipp","year":"2024","unstructured":"Leipp F, Vialaret J, Mohaupt P, Coppens S, Jaffuel A, et al. Glial fibrillary acidic protein in Alzheimer\u2019s disease: a narrative review. Brain Commun. 2024;6:fcae396.","journal-title":"Brain Commun"},{"key":"1323_CR22","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1007\/s12035-019-1589-z","volume":"56","author":"C Bagnall-Moreau","year":"2019","unstructured":"Bagnall-Moreau C, Chaudhry S, Salas-Ramirez K, Ahles T, Hubbard K. Chemotherapy-induced cognitive impairment is associated with increased inflammation and oxidative damage in the hippocampus. Mol Neurobiol. 2019;56:7159\u201372.","journal-title":"Mol Neurobiol"},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.3390\/cancers13164198","volume":"13","author":"G Schroyen","year":"2021","unstructured":"Schroyen G, Blommaert J, van Weehaeghe D, Sleurs C, Vandenbulcke M, et al. Neuroinflammation and its association with cognition, neuronal markers and peripheral inflammation after chemotherapy for breast cancer. Cancers (Basel). 2021;13:4198.","journal-title":"Cancers (Basel)"},{"key":"1323_CR24","doi-asserted-by":"publisher","first-page":"e0244612","DOI":"10.1371\/journal.pone.0244612","volume":"15","author":"M Arce Renter\u00eda","year":"2020","unstructured":"Arce Renter\u00eda M, Gillett SR, McClure LA, Wadley VG, Glasser SP, et al. C-reactive protein and risk of cognitive decline: the REGARDS study. PLoS ONE. 2020;15:e0244612.","journal-title":"PLoS ONE"},{"key":"1323_CR25","doi-asserted-by":"crossref","unstructured":"Dahalia M, Gupta S, Majid H, Vohora D, Nidhi. Pirfenidone regulates seizures through the HMGB1\/TLR4 axis to improve cognitive functions and modulate oxidative stress and neurotransmitters in PTZ-induced kindling in mice. Front Pharmacol. 2025;15:1528032.","DOI":"10.3389\/fphar.2024.1528032"},{"key":"1323_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2174\/1570159X18666200221113842","volume":"18","author":"A Das","year":"2020","unstructured":"Das A, Ranadive N, Kinra M, Nampoothiri M, Arora D, Mudgal J. An overview on chemotherapy-induced cognitive impairment and potential role of antidepressants. Curr Neuropharmacol. 2020;18:838\u201351.","journal-title":"Curr Neuropharmacol"},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"oyae268","DOI":"10.1093\/oncolo\/oyae268","volume":"30","author":"A Kerkmann","year":"2025","unstructured":"Kerkmann A, Schinke C, Dordevic A, Kern J, Bangemann N, et al. Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study. Oncologist. 2025;30:oyae268.","journal-title":"Oncologist"},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"117085","DOI":"10.1016\/j.taap.2024.117085","volume":"492","author":"M Barbosa-Azevedo","year":"2024","unstructured":"Barbosa-Azevedo M, Dias-Carvalho A, Carvalho F, Costa VM. Chemotherapy-induced cognitive impairment and glia: a new take on chemobrain? Toxicol Appl Pharmacol. 2024;492:117085.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"115391","DOI":"10.1016\/j.bbr.2024.115391","volume":"480","author":"OJ Haller","year":"2025","unstructured":"Haller OJ, Semendric I, Collins-Praino LE, Whittaker AL, George RP. Changes in cognition and astrocytic reactivity in a female rodent model of chemotherapy-induced cognitive impairment are variable both acutely and chronically. Behav Brain Res. 2025;480:115391.","journal-title":"Behav Brain Res"},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D\u2019Anna L, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158\u201372.","journal-title":"Nat Rev Neurol"},{"key":"1323_CR31","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3390\/ijms21093158","volume":"21","author":"T Qin","year":"2020","unstructured":"Qin T, Prins S, Groeneveld GJ, Van Westen G, de Vries HE, et al. Utility of animal models to understand human Alzheimer\u2019s disease, using the mastermind research approach to avoid unnecessary further sacrifices of animals. Int J Mol Sci. 2020;21:3158.","journal-title":"Int J Mol Sci"},{"key":"1323_CR32","doi-asserted-by":"publisher","first-page":"e0151890","DOI":"10.1371\/journal.pone.0151890","volume":"11","author":"W Zhou","year":"2016","unstructured":"Zhou W, Kavelaars A, Heijnen CJ. Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice. PLoS ONE. 2016;11:e0151890.","journal-title":"PLoS ONE"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:17:43Z","timestamp":1759763863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01323-8","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"23 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University Clinical Research Ethics Committee (dated 24.08.2022, decision no. 14\/X).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Both the patients in the study group and the healthy volunteers were provided with a detailed informed consent form. The form outlined the purpose of the study, how and why blood samples would be taken, what tests would be conducted, and how the samples would be disposed of. After the form was read aloud, participants were asked to read it themselves. It was clearly explained that their treatment and follow-up care would not be affected by this study or the blood samples taken. Participants were informed that the study had received ethical approval and that none of their demographic or clinical data would be shared with the public or third parties beyond scientific publication. It was also made clear to both groups that the study would not impose any financial burden on them, nor would they receive any financial benefit. Participants were reminded that they had the right to withdraw from the study at any stage without consequence.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}